Celgene co-founder Sol Barer bags a Johns Hopkins immuno-oncology spinout in buyout
A few weeks ago, Johns Hopkins Professor Jonathan Schneck published new research showing how the biomimetic nano beads he had created in the lab could work with a checkpoint inhibitor in fighting cancer. These beads were designed to act as antigen presenting cells aimed at whipping up a full scale killer T cell attack on cancer as the checkpoint stripped the cancer cells of their built-in defense system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
